Binds Hormone, Lymphokine, Cytokine, Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Intercellular Mediator, Or Neurotransmitter (e.g., Insulin, Human Chorionic Gonadotropin, Glucagon, Cardiodilatin, Interleukin, Interferon, Norepinephrine, Epinephrine, Acetylcholine, Etc.) Patents (Class 530/389.2)
-
Publication number: 20120093830Abstract: Disclosed are ligands that have binding specificity for interleukin-13 (IL-13), or for IL-4 and IL-13. Also disclosed are methods of using these ligands. In particular, the use of these ligands for treating allergic asthma is described.Type: ApplicationFiled: May 13, 2009Publication date: April 19, 2012Inventor: Inusha De Silva
-
Publication number: 20120093833Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.Type: ApplicationFiled: October 10, 2011Publication date: April 19, 2012Inventors: Juan Carlos Almagro, William DuBell, Johan Fransson, Jose Pardinas
-
Publication number: 20120096569Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: ApplicationFiled: December 21, 2011Publication date: April 19, 2012Inventors: Jill Giles-Komar, David Knight, David Peritt, Mohit Trikha
-
Publication number: 20120093839Abstract: In a broad aspect the present invention generally relates to novel dimer-complexes (herein called “non-fused-dimers” or NFDs) comprising single variable domains, methods of making these complexes and uses thereof. These non-covalently bound dimer-complexes consist of two identical monomers that each comprises of one or more single variable domains (homodimers) or of two different monomers that each comprises on or more single variable domains (heterodimers). The subject NFDs have typically altered e.g. improved binding characteristics over their monomelic counterpart. The NFDs of the invention may further be engineered through linkage by a flexible peptide or cysteines in order to improve the stability. This invention also describes conditions under which such NFDs are formed and conditions under which the formation of such dimers can be avoided.Type: ApplicationFiled: March 2, 2010Publication date: April 19, 2012Applicant: Ablynx N.V.Inventors: Ann Brige, Christine Labeur, Marc Jozef Lauwereys
-
Publication number: 20120082682Abstract: The present invention relates to antigen binding proteins to human IL-13, including anti-IL-13 antibodies and anti-IL-3/anti-IL-4 mAbdAbs, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as asthma or IPF.Type: ApplicationFiled: May 26, 2010Publication date: April 5, 2012Inventors: Claire Ashman, Jonathan Henry Ellis, Paul Andrew Hamblin, Alan Peter Lewis, Martin Anibal Orecchia
-
Publication number: 20120082681Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/1L18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: ApplicationFiled: October 4, 2011Publication date: April 5, 2012Applicant: NOVARTIS AGInventors: José M. CARBALLIDO HERRERA, Stefan HARTLE, Christoph HEUSSER, Ingo KLAGGE, Andrea POLZER, Christoph SCHWAERZLER, Gabriela WOCHNIK-VELTRUP
-
Publication number: 20120076798Abstract: Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.Type: ApplicationFiled: September 22, 2011Publication date: March 29, 2012Applicants: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY, KYOWA HAKKO KIRIN CO., LIMITEDInventors: Steven W. Granger, Shinichiro Kato, Carl F. Ware
-
Publication number: 20120076796Abstract: The present invention relates to amino acid sequences that are directed against proteins from the group of the Angiopoietin/Tie family such as Tie1, Tie2, Ang1, Ang2, Ang3, Ang4, Angptl1, Angptl12, Angptl13, Angptl14, Angptl15, Angptl16, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more of such amino acid sequences.Type: ApplicationFiled: December 10, 2009Publication date: March 29, 2012Applicant: Ablynx N.V.Inventors: Maria Gonzalez Pajuelo, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Peter Vanlandschoot
-
Publication number: 20120066775Abstract: The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.Type: ApplicationFiled: October 1, 2010Publication date: March 15, 2012Inventors: Sheau Yu Hsu, Aaron J.W. Hsueh
-
Publication number: 20120064090Abstract: Provided are a pharmaceutical composition which enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, wherein the cancer has resistance to the molecular target drug, and a cancer therapeutic agent effective against a cancer having resistance to a molecular target drug, such as gefitinib and erlotinib. The pharmaceutical composition comprising an HGF-MET receptor pathway inhibitor enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, even though the cancer has resistance to the molecular target drug. The cancer therapeutic agent comprising a molecular target drug in combination with an HGF-MET receptor pathway inhibitor is effective against a cancer having resistance to the molecular target drug.Type: ApplicationFiled: October 9, 2009Publication date: March 15, 2012Applicant: KRINGLE PHARMA INC.Inventors: Seiji Yano, Kunio Matsumoto
-
Publication number: 20120065094Abstract: This disclosure relates to methods and kits for diagnosing osteoarthritis and for determining the progression of osteoarthritis in a subject.Type: ApplicationFiled: September 14, 2011Publication date: March 15, 2012Applicant: NEW YORK UNIVERSITYInventors: Mukundan Attur, Steven B. Abramson
-
Publication number: 20120064064Abstract: The present invention relates to antigen binding proteins comprising an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the heavy chain comprises an epitope binding domain linked to the n-terminus of CH1-CH2-CH3, and the light chain comprises an epitope binding domain linked to the n-terminus of CL, wherein one or more epitope-binding domains are linked to the C-terminus of the immunoglobulin heavy chain, and/or one or more epitope-binding domains are linked to the C-terminus of the immunoglobulin light chain, methods for making such proteins, and uses thereof.Type: ApplicationFiled: May 26, 2010Publication date: March 15, 2012Inventors: Thil Dinuk Batuwangala, Laurent Jespers, Michael Steward
-
Patent number: 8133978Abstract: The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.Type: GrantFiled: May 23, 2007Date of Patent: March 13, 2012Assignee: Glaxo Group LimitedInventors: Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin
-
Publication number: 20120058052Abstract: The invention relates to a method and apparatus for pre-hatch avian embryo sex determination. In particular, the invention relates to a non-invasive method and apparatus for in-ovo determining the sex of avian species while in the egg and allowing to sort the eggs into groups consisting primarily of either male or female embryos. The method comprises the steps of introducing into the egg an antibody designed to match with a sex specific antigen on the embryo, which antibody is labelled, allowing the labelled antibody to migrate to and bind with the sex specific antigen on the embryo, detecting binding of the labelled antibodies on the embryo using detection means positioned outside of the egg.Type: ApplicationFiled: March 12, 2010Publication date: March 8, 2012Applicant: PRINZEN B.V.Inventors: Eddy Decuypere, Frank Fey
-
Publication number: 20120052566Abstract: The invention provides VEGF-C antagonists, such as anti-VEGF-C antibodies, and their use in the prevention and treatment of tumor progression.Type: ApplicationFiled: September 15, 2010Publication date: March 1, 2012Inventors: Anil D. Bagri, Germaine Fuh, Chingwei V. Lee
-
Publication number: 20120045438Abstract: The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.Type: ApplicationFiled: August 11, 2009Publication date: February 23, 2012Inventors: Ronald V. Swanson, Ellen Chi, Gopalan Raghunathan, Shanrong Zhao, Johan Fransson, Wendy Cordier, Hong Mimi Zhou, Juan C. Almagro, Linus Hyun, Jill Giles-Komar, Karyn T. O'Neil, Jill M. Carton, Alexey V. Teplyakov, Yiqing Feng
-
Publication number: 20120045391Abstract: The invention relates to antibodies or fragments thereof specific for insulin-like growth factor binding protein-7 (IGFBP7). A method of raising anti-IGFBP7 single domain antibodies is also disclosed and specific antibody clones are described, along with their binding characteristics. The anti-IGFBP7 antibodies may be useful as diagnostic tools for detecting neoplastic diseases involving tumor angiogenesis, and a variety of other angiogenesis associated diseases.Type: ApplicationFiled: October 14, 2009Publication date: February 23, 2012Applicant: National Research Council CanadaInventors: Daniva Stanimirovic, Abedelnasser Abulrob, Maria Moreno
-
Publication number: 20120045453Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.Type: ApplicationFiled: October 27, 2011Publication date: February 23, 2012Inventors: YAN CHEN, DEBRA GARDNER, DAVID M. KNIGHT, MICHAEL W. LARK, BAILIN LIANG, DAVID J. SHEALY, XIAO-YU R. SONG, VEDRANA STOJANOVIC-SUSULIC, RAYMOND W. SWEET, SUSAN H. TAM, SHENG-JIUN WU, JING YANG, DAVID MATTHEW MARQUIS, ERIC MICHAEL SMITH, ALAIN PHILIPPE VASSEROT
-
Publication number: 20120041181Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.Type: ApplicationFiled: January 9, 2009Publication date: February 16, 2012Inventors: Oliver Hill, Marcus Branschaedel, Christian Gieffers, Meinolf Thiemann
-
Publication number: 20120034234Abstract: The invention is in the field of molecular immunology, more in particular in the field of the prevention or treatment of autoimmune diseases, more in particular systemic sclerosis or scleroderma. The invention is based on the observation that SSC patients have an elevated plasma level of CXCL4. This was found to contribute to the pathogenesis of SSc, in particular fibrosis. When CXCL4 was neutralized in in vitro experiments, the fibrotic effects could be neutralized. This led us to conclude that SSc may be cured by reducing the plasma level of CXCL4. The invention therefore relates to a method for treatment or prevention of fibrosis in patients with scleroderma, wherein the plasma level of CXCL4 is reduced.Type: ApplicationFiled: March 8, 2010Publication date: February 9, 2012Applicant: STICHTING KATHOLIEKE UNIVERSITEITInventor: Timothy Ruben Dirk Jan Radstake
-
Publication number: 20120034237Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.Type: ApplicationFiled: July 29, 2011Publication date: February 9, 2012Applicant: AMGEN INC.Inventors: Thomas C. BOONE, Jonathan D. OLINER
-
Publication number: 20120034160Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.Type: ApplicationFiled: August 2, 2011Publication date: February 9, 2012Inventors: Tariq Ghayur, Junjian Liu, Peter C. Isakson
-
Publication number: 20120029472Abstract: TNFR25 compositions enhance the immune response against antigens. Administration of TNFR25 agonists was found to enhance tumor rejection, responses against viral diseases and other infectious organisms.Type: ApplicationFiled: December 21, 2009Publication date: February 2, 2012Applicant: University of MiamiInventors: Eckhard R. Podack, Natasa Strbo, Vadim Deyev, Taylor Schreiber
-
Publication number: 20120020983Abstract: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.Type: ApplicationFiled: October 8, 2008Publication date: January 26, 2012Applicant: The Regents of the University of CaliforniaInventors: Jonathan Braun, Lynn K. Gordon, Kaori Shimazaki, Madhuri Wadehra, Kathy A. Kelly, Anna M. Wu
-
Publication number: 20120020960Abstract: Compositions and methods for an immunotherapeutic approach for human breast cancer is provided herein. Any antagonist of thymic stromal lymphopoietin (TSLP) and/or OX40L to inhibit tumor development and IL-13 secretion by blocking the upregulation of OX40L by DCs exposed to breast cancer, thereby blocking their capacity to generate inflammatory IL-13+TNF?+IL-10negCD4+ T cells (Th2 cells). Thus, TSLP, and/or down-stream pathways, represent novel potential therapeutic targets against human breast cancer.Type: ApplicationFiled: July 22, 2011Publication date: January 26, 2012Applicant: Baylor Research InstituteInventors: Anna Karolina Palucka, Jacques F. Banchereau
-
Publication number: 20120020985Abstract: The invention provides the antibody D9.2 and antibody molecules based on D9.2 which bind interleukin-17 receptor B. These may be useful in therapy, e.g. the treatment of asthma, ulcerative colitis or Crohn's disease.Type: ApplicationFiled: March 31, 2010Publication date: January 26, 2012Applicant: Medical Research CouncilInventors: Andrew Neil James McKenzie, Daniel Neill
-
Publication number: 20120021431Abstract: The present invention provides a new method and kit for determining the overload of atrium or ventricle in a subject comprising at least a step of measuring levels of proBNP-108 in a sample from the subject. The disclosed methods and kits are useful, for example, in the diagnosis, prevention and/or treatment of cardiac diseases, particularly heat failure, aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, and atrial fibrillation.Type: ApplicationFiled: February 25, 2011Publication date: January 26, 2012Applicants: PRESIDENT OF NATIONAL CARDIOVASCULAR CENTER, SHIONOGI & CO., LTD.Inventors: Toshio Nishikimi, Naoto Minamino
-
Publication number: 20120014958Abstract: The present invention relates to soluble and stable anti-VEGF immunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: June 25, 2009Publication date: January 19, 2012Applicant: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Leonardo Borras, David Urech, Tea Gunde
-
Publication number: 20120016109Abstract: The present invention provides isolated polypeptides having an amino acid sequence having at least 70% identity to SEQ ID NO:20, wherein the polypeptide has ER-?36 activity. The invention further provides methods for identifying agents that bind to such polypeptides, methods for detecting such polypeptides, and methods for altering the activity of such polypeptides. Also provided are antibodies that specifically bind to an amino acid sequence depicted at SEQ ID NO:1, or an immunogenic fragment thereof, and methods for making and using such antibodies.Type: ApplicationFiled: July 6, 2011Publication date: January 19, 2012Applicant: CREIGHTON UNIVERSITYInventor: Zhao Yi Wang
-
Publication number: 20120014941Abstract: The present invention concerns antibodies to Bv8 and the uses of same.Type: ApplicationFiled: December 22, 2010Publication date: January 19, 2012Inventors: Xiumin Wu, Yan Wu, Lanlan Yu, Napoleone Ferrara, Wei-Ching Liang, Yu-Ju G. Meng, Janet Tien
-
Publication number: 20120014967Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.Type: ApplicationFiled: May 17, 2011Publication date: January 19, 2012Applicant: XOMA TECHNOLOGY LTD.Inventors: Linda Masat, Mary Haak-Frendscho, Gang Chen, Arnold Horwitz, Marina Roell
-
Publication number: 20120006716Abstract: The present invention relates to novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: ApplicationFiled: September 23, 2011Publication date: January 12, 2012Applicant: FEMTA PHARMACEUTICALS, INC.Inventors: Gerhard Frey, Hwai Wen Chang, Jay Short
-
Patent number: 8093363Abstract: Human TNF-gamma-alpha and TNF-gamma-beta polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such polypeptides to inhibit cellular growth, for example in a tumor or cancer, for facilitating wound-healing, to provide resistance against infection, induce inflammatory activities, and stimulating the growth of certain cell types to treat diseases, for example restenosis. Also disclosed are diagnostic methods for detecting a mutation in the TNF-gamma-alpha and TNF-gamma-beta nucleic acid sequences or overexpression of the TNF-gamma-alpha and/or TNF-gamma-beta polypeptides. Antagonists against such polypeptides and their use as a therapeutic to treat cachexia, septic shock, cerebral malaria, inflammation, arthritis and graft-rejection are also disclosed.Type: GrantFiled: September 10, 2010Date of Patent: January 10, 2012Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Jian Ni, Craig A. Rosen, Jun Zhang
-
Publication number: 20120003225Abstract: Methods, kits, and compositions for detecting and/or treating cancer based on detecting and/or administering an antibody, which can optionally be a bispecific antibody, having the immunoreaction characteristics of a cancer-associated autoantibody; an antigen for a cancer-associated autoantibody; or both an antibody having the immunoreaction characteristics of a cancer-associated autoantibody and an antigen for a cancer-associated autoantibody, in or to a subject in need thereof.Type: ApplicationFiled: May 11, 2009Publication date: January 5, 2012Applicant: DUKE UNIVERSITYInventors: Edward F. Patz, JR., Michael J. Campa, Elizabeth B. Gottlin
-
Publication number: 20120005127Abstract: Disclosed are methods for improvement of beta cell function in a subject using an anti-IL-1? antibody or fragment thereof.Type: ApplicationFiled: September 4, 2009Publication date: January 5, 2012Applicant: XOMA TECHNOLOGY LTD.Inventors: Patrick J. Scannon, Alan M. Solinger, Robert J. Bauer
-
Publication number: 20120003237Abstract: The present invention relates to binding agents for WISE, and includes for their manufacture and use.Type: ApplicationFiled: September 15, 2011Publication date: January 5, 2012Applicant: AMGEN INC.Inventors: Xueming QIAN, Kevin Graham, Grant Shimamoto, Barbara S. Tipton, Mei-Mei Tsai, Aaron George Winters, Li Zhang
-
Publication number: 20120003235Abstract: The instant invention is based, at least in part on the identification of a new class of antibodies that result, e.g., in improved LT blocking capabilities. Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize LT?R signaling are also provided.Type: ApplicationFiled: December 31, 2009Publication date: January 5, 2012Applicant: BIOGEN IDEC MA INC.Inventors: Ann M. Ranger, Ellen Garber, Justin A. Caravella, Alexey A. Lugovskoy, Joseph Arndt, Frederick R. Taylor, Giovanna Antognetti, Eric Day
-
Publication number: 20120003226Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, decreased insulin production, hyperglycemia, hypoinsulinemia, metabolic syndrome, Type 1 diabetes and obesity, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.Type: ApplicationFiled: September 4, 2009Publication date: January 5, 2012Applicant: XOMA TECHNOLOGY LTD.Inventors: Patrick J. Scannon, Alan M. Solinger, Robert J. Bauer
-
Publication number: 20120004289Abstract: The instant invention provides methods and compositions for the diagnosis and treatment of cancer. The invention also provides method and compositions for determining if a subject is, or is at risk of becoming, chemoresistant.Type: ApplicationFiled: March 5, 2010Publication date: January 5, 2012Applicant: The Johns Hopkins UniversityInventors: Jin Song, Zhen Zhang
-
Patent number: 8088618Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.Type: GrantFiled: September 29, 2008Date of Patent: January 3, 2012Assignee: Genentech, Inc.Inventors: Sek Chung Fung, Matthew Moyle, Mason Lu, Changning Yan, Sanjaya Singh, Dan Huang
-
Publication number: 20110318749Abstract: The present invention relates to methods and kits for identifying, quantifying and isolating regulatory T cells, to methods and kits for diagnosing or monitoring autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer, cancer treatment and/or organ transplantation based on regulatory T cell quantity, to methods and kits for predicting responses to therapy for autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer and/or organ transplantation based on regulatory T cell quantity, and to methods and kits for therapy using isolated regulatory T cells.Type: ApplicationFiled: April 15, 2011Publication date: December 29, 2011Applicant: CENTENARY INSTITUTE OF CANCER MEDICINE AND CELL BIOLOGYInventors: Barbara Denise FAZEKAS DE ST GROTH, Anthony Dominic Kelleher, Alan Lee Landay, Sarah Christina Sasson, Nabila Seddiki, John James Zaunders
-
Publication number: 20110318353Abstract: The present invention relates to target binding members (e.g., antibodies) that bind a specified epitope of human IL-25. The invention also relates to target binding members (e.g., antibodies) that comprise one or more humanized antibody VL domain sequences and bind IL-25. The invention further relates to compositions comprising target binding members (e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease).Type: ApplicationFiled: March 30, 2011Publication date: December 29, 2011Inventors: Juan Carlos Almagro, Patrick Branigan, Colleen Kane, William Strohl, Susann Taudte, Mark Tornetta, John Wheeler
-
Publication number: 20110319327Abstract: The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.Type: ApplicationFiled: April 27, 2011Publication date: December 29, 2011Applicant: Genentech, Inc.Inventors: Napoleone Ferrara, Sophia S. Kuo
-
Publication number: 20110318764Abstract: Muscle degenerative diseases can be detected in the early stage and the therapeutic efficacy of a therapeutic agent and/or a therapy method for the diseases can be determined by measuring 11,15-dioxo-9?-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid (referred to as “Tetranor-PGDM”, hereinbelow) in a sample isolated from a subject.Type: ApplicationFiled: March 8, 2010Publication date: December 29, 2011Applicants: OSAKA BIOSCIENCE INSTITUTE, TAIHO PHARMACEUTICAL CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Yoshihiro Urade, Kosuke Aritake, Toshihiko Maruyama, Shinya Kamauchi, Shin'ichi Takeda, Akinori Nakamura
-
Publication number: 20110318301Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.Type: ApplicationFiled: March 30, 2011Publication date: December 29, 2011Inventors: David P. Arnott, Austin L. Gumey, Philip E. Hass, James M. Lee, Yan Wu
-
Publication number: 20110311546Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.Type: ApplicationFiled: June 9, 2011Publication date: December 22, 2011Inventors: Jonathan Daniel Oliner, Kevin Graham
-
Patent number: 8080638Abstract: The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFN?”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, 1, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFN? protein subtype D. Examples of bioactivity for measurement include activation of the M×A promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFN? subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFN? related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.Type: GrantFiled: February 9, 2006Date of Patent: December 20, 2011Assignee: Baylor Research InstituteInventors: Jacques Branchereau, Kiley Prilliman, Virginia Pascual, Anna Karolina Palucka
-
Publication number: 20110306513Abstract: The present invention relates to the elucidation of a gene that can act as a novel marker for liver cancer diagnosis and to diagnostic and prognostic measurements of liver cancer using the same. More specifically, it relates to a diagnosis kit that enables diagnostic and prognostic measurement of a liver cancer using a preparation that measures expression levels of at least one gene selected from a group of liver cancer diagnosis markers consisting of S100P, NK4, CCL20, CSPG2, PLAU, MMP12, ESM-1, ABHD7, HCAPG, CXCL-3, Col5A2, MAGEA, GSN, CDC2, CST1, MELK, ATAD2, FAP and MSN and/or a method for diagnostic and prognostic measurement of liver cancer using the same. These have been discovered using normal liver tissues and liver cancer tissues collected from the same liver cancer patient of the present invention and represent the markers whose accuracy and reliability have been greatly improved as markers of liver cancer.Type: ApplicationFiled: December 3, 2009Publication date: December 15, 2011Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Eun Young Song, Hee Gu Lee, Young II Yeom, Na Young Ji, Jung II Lee, Min A. Kang, Young Joo Kim, Yoon Hee Kang, Jae Wha Kim
-
Publication number: 20110300148Abstract: The present invention relates to small peptides derived from a cytokine, interleukin-4 (IL-4), capable of binding to the IL-4 receptors and inhibiting macrophage activation, and thereby preventing the onset of inflammatory response. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein IL-4 plays a prominent role.Type: ApplicationFiled: November 17, 2009Publication date: December 8, 2011Inventors: Elisabeth Bock, Vladimir Berezin
-
Publication number: 20110301334Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.Type: ApplicationFiled: June 7, 2011Publication date: December 8, 2011Inventors: Sunil Bhakta, Jagath R. Junutula